View Future GrowthCuris 過去の業績過去 基準チェック /06Curisは3%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで17.9%毎年増加している。売上は成長しており、年平均0.4%の割合である。主要情報2.96%収益成長率18.12%EPS成長率Biotechs 業界の成長-14.59%収益成長率0.41%株主資本利益率-138.81%ネット・マージン-80.29%前回の決算情報31 Dec 2025最近の業績更新Curis, Inc. to Report Q4, 2025 Results on Mar 19, 2026Mar 13Curis, Inc. to Report Q3, 2025 Results on Nov 06, 2025Oct 31Curis, Inc. to Report Q2, 2025 Results on Aug 05, 2025Jul 29Curis, Inc. to Report Q1, 2025 Results on May 06, 2025Apr 29Curis, Inc. to Report Q4, 2024 Results on Mar 31, 2025Mar 29Third quarter 2024 earnings released: US$1.70 loss per share (vs US$2.13 loss in 3Q 2023) Nov 17すべての更新を表示Recent updatesCuris, Inc. Receives Notice of Nasdaq Delisting Due to Bid Price Non-ComplianceMay 02Curis, Inc., Annual General Meeting, May 19, 2026Apr 13Curis, Inc. to Report Q4, 2025 Results on Mar 19, 2026Mar 13Curis, Inc. Receives Written Notice from the Nasdaq Stock MarketFeb 10Curis, Inc. announced that it has received $20.195 million in fundingJan 09Curis, Inc. announced that it expects to receive $20.195 million in fundingJan 08Curis, Inc. Provides Updated Data from its Frontline AML Triplet StudyDec 09Curis, Inc. to Report Q3, 2025 Results on Nov 06, 2025Oct 31Nasdaq Grants Exception Period to Curis, Inc. to Regain ComplianceOct 25Curis, Inc. Receives Notice from Nasdaq Due to MVLS Requirement Non-ComplianceAug 23Curis, Inc. to Report Q2, 2025 Results on Aug 05, 2025Jul 29Curis, Inc. has filed a Follow-on Equity Offering in the amount of $3.499997 million.Jul 02Curis, Inc. to Report Q1, 2025 Results on May 06, 2025Apr 29Curis, Inc., Annual General Meeting, May 20, 2025Apr 03Curis, Inc. to Report Q4, 2024 Results on Mar 31, 2025Mar 29Curis, Inc. has filed a Follow-on Equity Offering in the amount of $4.758381 million.Mar 28Curis Receives Non-Compliance Notice from Nasdaq Regarding MVLS RequirementFeb 28Curis, Inc. Announces Additional Data from Take Aim Leukemia StudyDec 10Third quarter 2024 earnings released: US$1.70 loss per share (vs US$2.13 loss in 3Q 2023) Nov 17Curis, Inc. to Report Q3, 2024 Results on Nov 14, 2024Nov 07New minor risk - Shareholder dilution Nov 01Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million.Oct 30Second quarter 2024 earnings released: US$2.03 loss per share (vs US$2.47 loss in 2Q 2023) Aug 02Curis, Inc. to Report Q2, 2024 Results on Aug 01, 2024Jul 25Curis, Inc. Announces Additional Data from Take Aim Leukemia StudyMay 16New major risk - Revenue and earnings growth May 13First quarter 2024 earnings released: US$2.05 loss per share (vs US$2.39 loss in 1Q 2023) May 08Curis, Inc. to Report Q1, 2024 Results on May 07, 2024May 01Curis, Inc., Annual General Meeting, May 21, 2024Apr 11New major risk - Revenue and earnings growth Mar 08Full year 2023 earnings released: US$8.96 loss per share (vs US$12.14 loss in FY 2022) Feb 09Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Feb 09Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024Feb 02Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma StudyDec 12Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023Oct 27Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2022) Aug 05Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023Jul 29U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BIDJul 07First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2022) May 07Full year 2022 earnings released: US$0.61 loss per share (vs US$0.50 loss in FY 2021) Mar 15Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDSDec 13Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.12 loss in 3Q 2021) Nov 11Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022Nov 03Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid PriceOct 27Curis, Inc. Elects Anne E. Borgman as Class I DirectorOct 16Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022Sep 23Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia StudyAug 31FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, IncAug 19Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.12 loss in 2Q 2021) Aug 06Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022Aug 06Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022Jul 29Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022Jul 02+ 1 more updateCuris, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth IndexJun 26+ 2 more updatesCuris Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)Jun 05First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021) May 06Curis, Inc., Annual General Meeting, May 26, 2022Apr 14Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 StudyApr 12Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)Apr 05Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic CancersMar 10Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 26Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022Feb 18Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid TumorsJan 07Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020) Nov 10Insufficient new directors Nov 01Insufficient new directors Oct 02Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2020) Aug 05Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromesJun 12First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.28 loss in 1Q 2020) May 14Curis Receives U.S. Food and Drug Administration Orphan Drug Designation for CA-4948 for the Treatment of AML and MDSApr 20Full year 2020 earnings released: US$0.61 loss per share (vs US$0.97 loss in FY 2019) Mar 18Curis, Inc. to Report Q4, 2020 Results on Mar 16, 2021Mar 10Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic MalignanciesFeb 10Curis Announces Initiation of Investigator-Sponsored Phase 2 Lucas Study of Ca-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic SyndromesFeb 03New 90-day high: €7.25 Jan 06New 90-day high: €6.70 Dec 12Curis, Inc. has completed a Follow-on Equity Offering in the amount of $147.500001 million.Dec 11Curis, Inc. Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's LymphomaDec 10New 90-day high: €1.17 Nov 25Third quarter 2020 earnings released: US$0.11 loss per share Nov 12Curis, Inc. to Report Q3, 2020 Results on Nov 10, 2020Nov 05Curi Announces Appointment of Jason Sandner as its Next Chief Executive Officer, Effective July 1, 2021Oct 16Curis, Inc. Announces Abstract for CI-8993 Accepted for Presentation At the Society for Immunotherapy of Cancer's 35th Anniversary Annual MeetingOct 15Curis, Inc. has completed a Follow-on Equity Offering in the amount of $17.5 million.Aug 06Curis, Inc. to Report Q2, 2020 Results on Aug 04, 2020Jul 31収支内訳Curis の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:CUS0 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 259-814030 Sep 2512-3714030 Jun 2511-3914031 Mar 2511-4216031 Dec 2411-4317030 Sep 2410-4520030 Jun 2410-4820031 Mar 2410-4819031 Dec 2310-4719030 Sep 2310-4718030 Jun 2310-4818031 Mar 2310-5219031 Dec 2210-5720030 Sep 2210-5920030 Jun 2211-5720031 Mar 2211-5219031 Dec 2111-4517030 Sep 2111-3916030 Jun 2110-3414031 Mar 2110-3013031 Dec 2011-3012030 Sep 2011-3112030 Jun 2011-3112031 Mar 2011-3212031 Dec 1910-3212030 Sep 199-2912030 Jun 199-3013031 Mar 1910-3214031 Dec 1810-3315030 Sep 1811-3515030 Jun 1811-4314031 Mar 1810-4815031 Dec 1710-5314030 Sep 179-5715030 Jun 178-7016031 Mar 178-6716031 Dec 168-6016030 Sep 167-6315030 Jun 168-4013031 Mar 168-3713031 Dec 158-5913030 Sep 158-5113030 Jun 157-51130質の高い収益: CUS0は現在利益が出ていません。利益率の向上: CUS0は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CUS0は利益を出していないが、過去 5 年間で年間3%の割合で損失を削減してきた。成長の加速: CUS0の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: CUS0は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 45% ) と比較することは困難です。株主資本利益率高いROE: CUS0は現在利益が出ていないため、自己資本利益率 ( -138.81% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 14:46終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Curis, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Brian SkorneyBairdJames BirchenoughBMO Capital Markets Equity ResearchJustin WalshB. Riley Securities, Inc.13 その他のアナリストを表示
U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BIDJul 07
Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDSDec 13
Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid PriceOct 27
Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022Sep 23
Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia StudyAug 31
Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022Aug 06
Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022Jul 02+ 1 more update
Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)Jun 05
Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 StudyApr 12
Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic CancersMar 10
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid TumorsJan 07
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromesJun 12
Curis Receives U.S. Food and Drug Administration Orphan Drug Designation for CA-4948 for the Treatment of AML and MDSApr 20
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic MalignanciesFeb 10
Curis Announces Initiation of Investigator-Sponsored Phase 2 Lucas Study of Ca-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic SyndromesFeb 03
Curis, Inc. Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's LymphomaDec 10
Curi Announces Appointment of Jason Sandner as its Next Chief Executive Officer, Effective July 1, 2021Oct 16
Curis, Inc. Announces Abstract for CI-8993 Accepted for Presentation At the Society for Immunotherapy of Cancer's 35th Anniversary Annual MeetingOct 15